BTIG Reiterates Buy Rating on Boston Scientific (BSX) following Bolt Medical deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Deutsche Bank Upgrades Boston Scientific (BSX) to Buy
January 10, 2025 7:08 AM ESTDeutsche Bank analyst Pito Chickering upgraded Boston Scientific (NYSE: BSX) from Hold to Buy with a price target of $108.00 (from $87.00).
The analyst comments "So the BSX story has become simpler, and as one of the best-in-class medtech names, we believe BSX is poised again to outperform in 2025, and we are upgrading the shares to Buy with a $108 price target which is 34x our 2026E EPS. There are many risks to our Buy thesis: (1) BSX is one of the most consensus longs within our coverage universe. So who might be the... More
